The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries

Abstract

One of the meanings of “reveal” is “to disclose through prophets”. In the world of pulmonary arterial hypertension (PAH), REVEAL refers more modestly to the Registry to EValuate Early and Long-term PAH Disease Management [1–3]. In the current issue of the European Respiratory Review , two of the key contributors to this modern era registry have elegantly summarised their recent findings and future research plans [4]. The ability to identify and evaluate factors that affect survival in patients with PAH is of critical interest to clinicians. The first of several registries (Patient Registry for the Characterization of Primary Pulmonary Hypertension), supported by the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute, was initiated in 1981 [5, 6 …